Literature DB >> 29494259

Symptom Burden in the First Year After Cancer Diagnosis: An Analysis of Patient-Reported Outcomes.

Lev D Bubis1, Laura Davis1, Alyson Mahar1, Lisa Barbera1, Qing Li1, Lesley Moody1, Paul Karanicolas1, Rinku Sutradhar1, Natalie G Coburn1.   

Abstract

Purpose Improvement in the quality of life of patients with cancer requires attention to symptom burden across the continuum of care, with the use of patient-reported outcomes key to achieving optimal care. Yet there have been few studies that have examined symptoms in the early postdiagnosis period during which suboptimal symptom control may be common. A comprehensive analysis of temporal trends and risk factors for symptom burden in newly diagnosed patients with cancer is essential to guide supportive care strategies. Methods A retrospective observational study was performed of patients who were diagnosed with cancer between January 2007 and December 2014 and who survived at least 1 year. Patient-reported Edmonton Symptom Assessment System scores, which are prospectively collected at outpatient visits, were linked to provincial administrative health care data. We described the proportion of patients who reported moderate-to-severe symptom scores by month during the first year after diagnosis according to disease site. Multivariable logistic regression models were constructed to identify risk factors for moderate-to-severe symptom scores. Results Of 120,745 patients, 729,861 symptom assessments were recorded within 12 months of diagnosis. For most symptoms, odds of elevated scores were highest in the first month, whereas nausea had increased odds of elevated scores up to 6 months after diagnosis. On multivariable analysis, cancer site, younger age, higher comorbidity, female sex, lower income, and urban residence were associated with significantly higher odds of elevated symptom burden. Conclusion A high prevalence of moderate-to-severe symptom scores was observed in cancers of all sites. Patients are at risk of experiencing multiple symptoms in the immediate postdiagnosis period, which underscores the need to address supportive care requirements early in the cancer journey. Patient subgroups who are at higher risk of experiencing moderate-to-severe symptoms should be targeted for tailored supportive care interventions.

Entities:  

Mesh:

Year:  2018        PMID: 29494259     DOI: 10.1200/JCO.2017.76.0876

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  35 in total

1.  1-2-3 Project: A Quality Improvement Initiative to Normalize and Systematize Palliative Care for All Patients With Cancer in the Outpatient Clinic Setting.

Authors:  Anjali V Desai; Virginia M Klimek; Kimberly Chow; Andrew S Epstein; Camila Bernal; Kelly Anderson; Molly Okpako; Robin Rawlins-Duell; Dana Kramer; Danielle Romano; Jessica I Goldberg; Judith E Nelson
Journal:  J Oncol Pract       Date:  2018-12       Impact factor: 3.840

2.  Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy.

Authors:  Qiuling Shi; Ju-Whei Lee; Xin Shelley Wang; Michael J Fisch; Victor T Chang; Lynne Wagner; Charles S Cleeland
Journal:  JCO Oncol Pract       Date:  2020-05-05

3.  Social disparities and symptom burden in populations with advanced cancer: specialist palliative care providers' perspectives.

Authors:  Anna Santos Salas; Sharon M Watanabe; Yoko Tarumi; Tracy Wildeman; Ana M Hermosa García; Bisi Adewale; Wendy Duggleby
Journal:  Support Care Cancer       Date:  2019-04-10       Impact factor: 3.603

4.  Gaps in the Management of Depression Symptoms Following Cancer Diagnosis: A Population-Based Analysis of Prospective Patient-Reported Outcomes.

Authors:  Julie Hallet; Laura E Davis; Elie Isenberg-Grzeda; Alyson L Mahar; Haoyu Zhao; Victoria Zuk; Lesley Moody; Natalie G Coburn
Journal:  Oncologist       Date:  2020-02-26

5.  Factors associated with receipt of symptom screening in the year after cancer diagnosis in a universal health care system: a retrospective cohort study.

Authors:  A L Mahar; L E Davis; L D Bubis; Q Li; R Sutradhar; N G Coburn; L Barbera
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

6.  Research priorities for the pan-Canadian Oncology Symptom Triage and Remote Support practice guides: a modified nominal group consensus.

Authors:  L A Jibb; D Stacey; M Carley; A Davis; I D Graham; E Green; L Jolicoeur; C Kuziemsky; C Ludwig; T Truant
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

Review 7.  Innovations in research and clinical care using patient-generated health data.

Authors:  Heather S L Jim; Aasha I Hoogland; Naomi C Brownstein; Anna Barata; Adam P Dicker; Hans Knoop; Brian D Gonzalez; Randa Perkins; Dana Rollison; Scott M Gilbert; Ronica Nanda; Anders Berglund; Ross Mitchell; Peter A S Johnstone
Journal:  CA Cancer J Clin       Date:  2020-04-20       Impact factor: 508.702

8.  Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.

Authors:  Julie Hallet; Laura E Davis; Alyson L Mahar; Calvin H L Law; Elie Isenberg-Grzeda; Lev D Bubis; Simron Singh; Sten Myrehaug; Haoyu Zhao; Kaitlyn Beyfuss; Lesley Moody; Natalie G Coburn
Journal:  Oncologist       Date:  2019-07-03

9.  Attrition in NRG Oncology's Radiation-Based Clinical Trials.

Authors:  Connie M Ulrich; Snehal Deshmukh; Stephanie L Pugh; Alexandra Hanlon; Christine Grady; Deborah Watkins Bruner; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-05-10       Impact factor: 7.038

10.  Misery Loves Company: Presenting Symptom Clusters to Urgent Care by Patients Receiving Antineoplastic Therapy.

Authors:  Bobby Daly; Kevin Nicholas; Dmitriy Gorenshteyn; Stefania Sokolowski; Lior Gazit; Lynn Adams; Jennie Matays; Lauren L Katzen; Yeneat O Chiu; Han Xiao; Rori Salvaggio; Abigail Baldwin-Medsker; Kimberly Chow; Judith Nelson; Mikel Ross; Kenneth K Ng; Alice Zervoudakis; Wendy Perchick; Diane L Reidy; Brett A Simon; Isaac Wagner
Journal:  J Oncol Pract       Date:  2018-07-17       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.